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Background:  The  effects  of  the  combination  of  angiotensin  II receptor  blocker  (ARB)  plus  dihydropyridine
calcium  channel  blockers  (DHP-CCBs),  which  is  known  as a potent  antihypertensive  drug  regimen,  on
cardiovascular  events  remain  unclear.
Objective:  The  purpose  of  this  post  hoc  subgroup  analysis  was  to  compare  the  incidence  of  major  adverse
cardiovascular  events  (MACE)  of  patients  treated  with  candesartan  and amlodipine  with  that  of  those
with  candesartan  and  non-amlodipine  CCBs  in hypertensive  patients  with  coronary  artery  disease  (CAD).
Methods:  HIJ-CREATE  was  a multicenter,  prospective,  randomized,  controlled  study  that  compared  the
effects  of candesartan-based  with  those  of  non-ARB-based  standard  therapy  on  MACE in 2049  hyperten-
sive  patients  with  CAD.  In  the candesartan  group,  a  total  of 335  patients  were  treated  with  DHP-CCBs
(amlodipine:  170  and  non-amlodipine-CCBs:  165)  at the  baseline.  In  this  sub-analysis,  we compared,
among  the  participants  allocated  to candesartan  regimen,  the  long-term  effects  of amlodipine  and
non-amlodipine  CCBs  that were  concomitantly  given  with  ARB,  although  the  choice  of  CCB  was  not
randomized.
Results:  The  median  follow-up  was  3.9 years.  Treatment  using  amlodipine  with  candesartan  reduced  the
risk of MACE  by  38% (hazard  ratio,  0.62;  95%  conﬁdence  interval,  0.41–0.94,  p =  0.025),  as  compared
to  patients  treated  with  non-amlodipine-CCBs  and  candesartan.  In a multivariate  analysis,  combi-
nation  therapy  of  candesartan  with  amlodipine  was  an independent  predictor  of  reduced  risk  of
MACE.
Conclusions:  The  results  suggest  that  the  combination  of amlodipine  and  candesartan  is more  beneﬁcial
in  reducing  MACE  in  hypertensive  patients  with  CAD  compared  to non-amlodipine-DHP-CCBs  in  combi-
nation  therapy  with  candesartan.  Further  investigation  in larger-scale  prospective  randomized  studies
is required  to  reach  any  conclusion  as  to the  superiority  of  combination  therapy  of  candesartan  with
3  Jap
amlodipine.
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Hypertension is highly prevalent, affecting approximately one
illion individuals worldwide [1,2]. Approximately 26.4% of the
dult population worldwide had hypertension in 2000, and this is
xpected to increase to 29.2% by 2025 [1]. Hypertension is a potent,
ndependent risk factor for myocardial infarction [3,4]. Despite the
ariety of treatment modalities available, hypertension remains
ndertreated and, subsequently, poorly controlled. The average
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number of drugs used to reach target blood-pressure levels in
recent clinical trials was  about 2.0 [5,6]. The aggregate of previous
studies suggests that at least 75% of patients will require combi-
nation therapy to achieve contemporary blood pressure targets
[7,8]. Consequently, initial therapy for hypertension with a com-
bination of drugs is recommended by both the seventh report of
the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC 7) and European guide-
lines for patients whose blood pressures are 20/10 mm Hg or more
above the goal [9,10]. An experimental study demonstrated that
the calcium-channel blocker (CCB) amlodipine effectively increases
the availability of vascular endothelial nitric oxide [11]. Another
study showed that the combined effects of amlodipine and an
angiotensin-converting enzyme inhibitor (ACEI), benazepril, on
vier Ltd. All rights reserved.
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female ratio, proportion of patients with acute coronary syndrome,
those undergoing percutaneous coronary intervention, systolic
blood pressure, and proportion of patients receiving aspirin.18 R. Koyanagi et al. / Journal 
itric oxide are greater than the effect with either drug alone, and
ombination therapy of CCB and an ACEI is beneﬁcial for managing
ardiac ischemia [12].
In the Avoiding Cardiovascular Events through Combination
herapy in Patients Living with Systolic Hypertension (ACCOM-
LISH) trial [13], a recent randomized trial, the investigators clearly
emonstrated the ACEI-CCB combination signiﬁcantly reduced car-
iovascular events in high-risk hypertensive patients. Angiotensin
I receptor blockers (ARBs) are well-tolerated in patients unable
o tolerate ACEIs [14]. The vasodilatory action of CCBs stimulates
ounterregulatory mechanisms such as sympathetic activation
nd activation of the renin-angiotensin-aldosterone system. These
echanisms reduce the blood pressure-lowering effects of CCBs
15–17]. ARBs act by blocking the vasoconstriction effect of
ngiotensin II at angiotensin receptor type-1, thus complementing
CB use for effective blood pressure-lowering [18]. In the Olme-
artan and Calcium Antagonists Randomized (OSCAR) Study, a
ecent randomized trial, the investigators demonstrated that the
RB and CCB combination reduced the incidence of cardiovascular
vents in elderly hypertensive patients with cardiovascular disease
19].
Previous studies [20–22] demonstrated that there is an inconsis-
ency for the renoprotective effect among several dihydropyridine
CBs. Among dihydropyridine CCBs, amlodipine is a well-studied
ne. To our knowledge, the impact of combination therapy of an
RB and amlodipine on the long-term outcome in hypertensive
atients with coronary artery disease (CAD) has not been studied.
he purpose of this post hoc subgroup analysis was to compare
he incidence of major adverse cardiovascular events (MACE) of
atients treated with candesartan and amlodipine with that of
hose with candesartan and non-amlodipine CCBs in hypertensive
atients with CAD.
atients and methods
tudy population and treatment
In the Heart Institute of Japan Candesartan Randomized Trial for
valuation in Coronary Artery Disease (HIJ-CREATE) study, a mul-
icenter, prospective, randomized, open-label, blinded-endpoint
rial conducted in Japan, the effects of ARB (candesartan)-based
herapy on MACE were compared with those of non-ARB-based
tandard therapy in hypertensive patients with CAD, which was
etected by angiography. The study methods and principal results
ave previously been published [23]. Brieﬂy, 2049 patients with
ypertension in whom angiography revealed CAD were randomly
ssigned to receive ARB (candesartan)-based (n = 1024) or non-
RB-based drug therapy (n = 1025). Among the total of 2049
ypertensive patients with CAD, 1024 participants were allo-
ated to the candesartan-based treatment arm. Among them, 335
eceived combination therapy with candesartan and DHP-CCB. In
he HIJ-CREATE study, combination therapy was prescribed at the
iscretion of the attending physician to reach the target blood pres-
ure. Of these 335 participants, candesartan was  combined with
mlodipine in 170, and with non-amlodipine-DHP-CCBs in 165
Fig. 1). Periodic follow-up was performed 6, 12, 24, 36, 48, and
0 months after assignment to conﬁrm the onset of events as end-
oints and the safety of agents. All patients were followed for 36
onths or more.
The appearance of MACE, including cardiovascular death, non-
atal myocardial infarction, unstable angina, heart failure, stroke,
nd other cardiovascular events requiring hospitalization was
stablished as a primary endpoint. In this sub-group analysis, we
valuated the usefulness of the combination therapy of candesar-
an with amlodipine in comparison with the combination therapy
f candesartan with non-amlodipine-DHP-CCBs.iology 62 (2013) 217–223
Statistical analysis
The background data are expressed as the mean ± SD and
percentage. The p-values were calculated using the two-tailed Stu-
dent’s t-test or Fisher’s exact test. To compare the two treatment
groups, we employed the log-rank test and Cox’s proportional
hazard model. Kaplan–Meier survival curves were generated by
the product-limit method. Intergroup differences were evaluated
with the use of the log-rank test. Predictors of subsequent MACE
were analyzed using Cox regression models. It was desirable to
include the traditional risk factors that were determined by ref-
erence to previous studies [24–26] in the proportional hazard
model. Multivariate analysis using the Cox proportional hazards
model was  performed to assess the relationship of the follow-
ing baseline characteristics to subsequent MACE: age ≥ 65 years,
male gender, previous percutaneous coronary intervention, aspirin
use, creatinine clearance > 60 ml/min, and combination therapy of
amlodipine with candesartan. The interaction of hypertension with
the effect of anti-hypertensive medical therapy was  analyzed using
a likelihood ratio test. Adjusted hazard ratios (HRs) with 95% CIs
were calculated for MACE. Statistical analysis was  conducted at an
independent statistical data center (Medical TOUKEI Corporation,
Tokyo, Japan) employing SPSS 15.0 (SPSS Inc., Chicago, Il, USA) and
SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
Among the total of 2049 hypertensive patients with CAD, 1024
participants were allocated to the candesartan-based treatment
arm. Among them, 335 received combination therapy with can-
desartan and DHP-CCB. Of these, candesartan was combined with
amlodipine besylate in 170, and with non-amlodipine-DHP-CCBs,
which were restricted to three CCBs, nifedipine CR, benidipine
hydrochloride, and cilnidipine in 165 (Fig. 1). Although the DHP-
CCBs were restricted to these four agents, the design of our database
did not allow a quantitative assessment of such medications. The
median follow-up period was  3.9 years. The backgrounds of the
subjects are presented in Table 1. There were no signiﬁcant differ-
ences between the two groups in background factors except theFig. 1. Flow of patients through the study. ARB, angiotensin II receptor blocker; CCB,
calcium channel blocker; DHP, dihydropyridine.
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Table  1
Baseline characteristics.
Variables Amlodipine + candesartan
(n = 170)
Non-amlodipine–DHP–CCB
+ candesartan (n = 165)
p-Value
Women 24 (14.1%) 42 (25.5%) 0.013
Age  (years) 65.5 ± 8.7 65 ± 9.5 0.604
Acute  coronary syndrome 35 (20.6%) 46 (27.9%) 0.127
Number of diseased vessels 0.699
≤  1 88 (51.8%) 95 (57.6%)
≥  2 82 (48.2%) 70 (42.4%)
Revascularization
Percutaneous coronary intervension 146 (85.9%) 125 (75.8%) 0.026
During enrolment hospitalization 85 (50.0%) 82 (49.7%) 1.000
Coronary artery bypass grafting 19 (11.2%) 14 (8.5%) 0.466
During enrolment hospitalization 0 (0.0%) 4 (2.4%) 0.058
Dyslipidaemia 104 (61.2%) 105 (63.6%) 0.654
Diabetes mellitus 77 (45.3%) 69 (41.8%) 0.582
Current smoker 63 (37.1%) 54 (32.7%) 0.424
Family history 40 (23.5%) 36 (21.8%) 0.794
Cerebrovascular disease 17 (10.0%) 23 (13.9%) 0.313
Peripheral vascular disease 8 (4.7%) 11 (6.7%) 0.485
Artrial ﬁbrillation 9 (5.3%) 3 (1.8%) 0.139
NYHA  functional class 0.228
I  139 (81.8%) 131 (79.4%)
II  25 (14.7%) 28 (17.0%)
III  3 (1.8%) 6 (3.6%)
IV  3 (1.8%) 0 (0%)
Body  mass index (kg/m2) 25.1 ± 2.7 24.8 ± 3.1 0.332
Systolic blood pressure (mmHg) 135.2 ± 16.7 139.0 ± 18.6 0.046
Diastolic blood pressure (mmHg) 75.1 ± 11.8 75.0 ± 11.9 0.953
Left  ventricular ejection fraction (%) 55.8 ± 10.6 55.3 ± 10.3 0.700
Total  cholesterol (mg/dL) 191.5 ± 29.8 197.2 ± 36.8 0.124
Triglyceride (mg/dL) 143 (108.5–190.5) 131 (93.0–200.0) 0.514
HDL-cholesterol (mg/dL) 44.3 ± 13.5 44.3 ± 11.9 0.967
Fasting blood sugar(mg/dL) 133.3 ± 59.1 122.8 ± 38.4 0.057
HbA1c (%) 6.2 ± 1.3 6.1 ± 1.3 0.843
Serum creatinine (mg/dL) 0.9 ± 0.3 0.9 ± 0.3 0.778
C-reactive protein (mg/dL) 0.17 (0.1–0.3) 0.2 (0.1–0.4) 0.196
Medications before randomization
ACE-Is 61 (35.9%) 57 (34.5%) 0.820
Diuretics 11 (6.5%) 17 (10.3%) 0.239
Calcium-channel blockers 158 (92.9%) 143 (86.7%) 0.070
-Blockers 78 (45.9%) 64 (38.8%) 0.224
ARBs  42 (24.7%) 38 (23.0%) 0.798
Medications at discharge
ACE-Is 2 (1.2%) 1 (0.6%) 1.000
Diuretics 9 (5.3%) 18 (10.9%) 0.071
-Blockers 87 (51.2%) 71 (43.0%) 0.155
Aspirin 165 (97.1%) 143 (86.7%) 0.0005
Antiplatelet agents 89 (53.0%) 76 (46.1%) 0.229
86 (52.1%) 0.383
79 (47.9%) 0.913
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The mean ofﬁce systolic blood pressure at the baseline in
he candesartan + amlodipine group was lower than in the
andesartan + non-amlodipine-CCBs group (135 ± 17 mmHg  and
39 ± 19 mmHg, respectively, p = 0.046). However, after 6 months
f treatment, there were no further signiﬁcant differences between
he two groups. The mean ofﬁce systolic blood pressures after
6 months of treatment in the candesartan + amlodipine and can-
esartan + non-amlodipine-CCBs groups were 132 ± 17 mmHg  and
33 ± 17 mmHg, respectively. The values after 48 months were
33 ± 16 mmHg  and 133 ± 15 mmHg, respectively (Fig. 2).
The mean heart rate at the baseline in the candesartan
 amlodipine group was lower than that in the candesartan
 non-amlodipine-CCBs group (67.3 ± 9.7 bpm vs. 69.6 ± 11.2 bpm,
espectively, p = 0.043). However, after 6 months of treatment,
here were no further signiﬁcant differences between the two
roups (Fig. 3).There were no signiﬁcant differences in any parameter of
ipid/glucose metabolism between the two groups, excluding the
bA1c value after 48 months and the HDL-cholesterol level after
0 months of treatment (Fig. 4).
AML(+)
165 154 146 141 140 97
170 164 161 156 149 105
Fig. 2. Mean patient blood pressure at baseline and during follow-up. AML,
amlodipine.
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Fig. 5. Cumulative event rates for primary endpoints in both treatment groups. DHP-
F
aFig. 3. Mean heart rate at baseline and during follow-up. AML, amlodipine.
MACE, as a primary endpoint, occurred in 37 patients (21.8%)
n the ARB + amlodipine group and 52 (31.5%) in the ARB + non-
mlodipine-CCBs group. In the former, the risk of MACE decreased
y 38% in comparison with the latter. The hazard ratio was  0.62,
nd the 95% conﬁdence interval ranged from 0.41 to 0.94 (p = 0.025)
Fig. 5). In the former, the risk of myocardial infarction and unsta-
le angina signiﬁcantly decreased (Table 2). The incidences of
yocardial infarction and unstable angina were 1.8% and 11.2%,
espectively (HR: 0.27 and 0.52, 95% CI: 0.76–0.998 and 0.29–0.91,
 = 0.049 and 0.022, respectively), lower than in the control group
6.1% and 20.0%, respectively).
In addition, when reviewing the hazard ratio after corrected fac-
or adjustment using Cox’s regression analysis, the risk of MACE
ig. 4. Changes in metabolic parameters in both groups: (A) total cholesterol level, (B) H
mlodipine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Hb, hemoglobinCCB,  dihydropyridine calcium channel blocker; MACE, major adverse cardiovascular
event.
in the ARB + amlodipine group was  signiﬁcantly lower than in the
ARB + non-amlodipine-CCBs group (Table 2).
Table 3 shows relative risks and 95% conﬁdence intervals for the
primary endpoint according to selected demographics. Most point
estimates demonstrated similar hazard ratios, and no statistical
heterogeneity was  identiﬁed among subgroups. Among them, male
gender, age younger than 65 years, and a lower level of C-reactive
protein (<2 mg/L) were associated with a signiﬁcant reduction in
MACEs, without any signiﬁcant interactions among patient char-
acteristics. It was desirable to include the traditional risk factors
DL cholesterol level, (C) LDL cholesterol level, and (D) hemoglobin A1c level, AML,
.
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Table  2
Hazard ratio for major adverse cardiovascular events.
Events Unadjusted Adjusted*
Amlodipine (+) Amlodipine (−) Hazard ratio (95%CI) p-Value Hazard ratio (95%CI) p-Value
Non-fatal MI  3 (1.8%) 10 (6.1%) 0.27 (0.76–0.998) 0.049 0.32 (0.08–1.21) 0.093
Unstable angina 19 (11.2%) 33 (20.0%) 0.52 (0.29–0.91) 0.022 0.52 (0.29–0.93) 0.026
Heart  failure 4 (2.4%) 6 (3.6%) 0.63 (0.18–2.24) 0.478 0.66 (0.18–2.45) 0.532
Stroke 7 (4.1%) 9 (5.5%) 0.74 (0.28–1.98) 0.547 0.72 (0.26–2.01) 0.535
Other cardiovascular 9 (5.3%) 5 (3.0%) 1.71 (0.57–5.11) 0.335 1.88 (0.59–6.01) 0.287
Cardiovascular death 2 (1.2%) 6 (3.6%) 0.31 (0.06–1.55) 0.155 0.55 (0.10–3.06) 0.497
MACE 37 (21.8%) 52 (31.5%) 0.62 (0.41–0.94) 0.025 0.63 (0.41–0.98) 0.040
MACE: major adverse cardiovascular events, MI:  myocardial infarction
* The hazard ratio was  adjusted for gender, percutaneous coronary intervension, systolic blood pressure, aspirin usage
Table 3
Adverse cardiovascular events with amlodipine(+) compared to non-amlodipine-CCBs by subgroup.
Adverse cardiovascular events (%) Hazard ratio (95%CI) p-Value p-Value for interaction
Amlodipine Non-amlodipine-CCBs
Sex
Female 4 (16.7%) 12 (28.6%) 0.573 (0.184–1.782) 0.336 0.919
Male  33 (22.6%) 40 (32.5%) 0.603 (0.380–0.956) 0.031
Age
<65yr  70 (17.1%) 70 (31.4%) 0.470 (0.233–0.950) 0.036 0.348
≥65yr  100 (25.0%) 95 (31.6%) 0.726 (0.427–1.236) 0.238
Body  mass index (kg/m2)
<25 86 (17.4%) 86 (29.1%) 0.533 (0.281–1.012) 0.054 0.299
25–30  78 (25.6%) 71 (35.2%) 0.638 (0.354–1.149) 0.134
≥30 6  (33.3%) 8 (25.0%) 1.538 (0.216–10.947) 0.667
Acute coronary syndrome
No 135 (22.2%) 119 (30.3%) 0.654 (0.403–1.062) 0.086 0.703
Yes  35 (20.0%) 46 (34.8%) 0.514 (0.211–1.252) 0.143
C-reactive protein
<2 mg/L 163 (21.5%) 156 (31.4%) 0.610 (0.395–0.941) 0.026 0.767
≥2  mg/L 7 (28.6%) 9 (33.3%) 0.750 (0.124–4.535) 0.754
Estimated GFR (ml/min./1.73m2)
≥60 110 (19.1%) 95 (26.3%) 0.666 (0.373–1.190) 0.170 0.846
<60  60 (26.7%) 69 (37.7%) 0.610 (0.327–1.138) 0.120
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CB, calcium channel blocker; CI, conﬁdence interval; GFR, glomerular ﬁltration rat
hich were determined by reference to previous studies in the
roportional hazard model. Furthermore several factors showed
igniﬁcant differences in the prevalence between the two groups
n the present subanalysis should also be included in the propor-
ional hazard model. The results are shown in Table 4. Multivariable
nalysis for predictors of subsequent MACE showed the combina-
ion therapy of ARB with amlodipine as an independent predictor
HR 0.626, 95% CI 0.402–0.975).
iscussionThe sub-analysis of the HIJ-CREATE study showed that combi-
ation therapy with candesartan and amlodipine more markedly
educed the incidence of MACE compared to that with candesartan
nd non-amlodipine-DHP-CCBs in hypertensive patients with CAD.
able 4
esults of multivariate analysis for predictors of MACE shown as adjusted HRs and
5%CIs.
Adjusted hazard ratios (95%CI) p-Value
Candesartan + amlodipine 0.626 (0.402–0.975) 0.038
Age ≥ 65 years 1.319 (0.832–2.091) 0.239
Male gender 0.655 (0.370 –1.159) 0.146
Previous PCI 1.049 (0.593–1.854) 0.870
Aspirin use 0.715 (0.336–1.522) 0.385
Creatinine clearance ≥ 60 0.814 (0.519–1.276) 0.369
ACE: major adverse cardiovascular events, PCI: percutaneous coronary interven-
ion..617 (0.405–0.941) 0.025
In particular, this therapeutic regimen decreased the incidence of
myocardial infarction and unstable angina, although there was no
signiﬁcant difference in the blood pressure at any point other than
the baseline during the study period, suggesting that the combina-
tion of candesartan and amlodipine exhibits vasoprotective actions
independent from blood pressure lowering effects, differing from
combination regimens with other CCBs.
In the recently published Avoiding Cardiovascular Events
through Combination Therapy in Patients Living with Systolic
Hypertension (ACCOMPLISH) trial, the investigators clearly demon-
strated the potential synergistic effect of amlodipine plus ACEI
compared with hydrochlorothiazide plus ACEI in high-risk patients
with hypertension [13]. In a recently published case–control study
of relatively low-risk patients with hypertension, treatment with
diuretics plus CCBs was associated with a higher risk of myocar-
dial infarction than treatment with diuretics plus  blockers or
diuretics plus ACEIs or ARBs [27]. Subsequently, the optimal combi-
nation therapy for the prevention of cardiovascular events among
hypertensive patients who require additional treatment for blood
pressure control is not known.
We have recently suggested that the combination of amlodipine
and candesartan had a more favorable effect on reducing cardio-
vascular events in patients with hypertension with CAD compared
to amlodipine-based therapy without candesartan [28]. Since the
HIJ-CREATE study was an open-label trial evaluating for hyper-
tension and CAD, we could not exclude the possibility that we
might overestimate the effects of candesartan-based therapy com-
pared to non-ARB standard therapy. It was  necessary to evaluate
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he usefulness of amlodipine therapy by comparison to other dihy-
ropyridine calcium channel blockers (DHP-CCBs) in participants
llocated to candesartan-based therapy in the HIJ-CREATE study.
Amlodipine and candesartan have both been shown to be as
ffective as or sometimes better than other antihypertensive agents
n terms of cardiovascular morbidity and mortality and associated
dverse events. In the Prospective Randomized Evaluation of the
ascular Effects of Norvasc Trial (PREVENT), amlodipine decreased
he risk of cardiovascular events including angioplasty by 31% in
omparison with the placebo group, and B-mode echography con-
rmed a signiﬁcant decrease in the carotid intima-media thickness
IMT) [29]. The Comparison of Amlodipine vs. Enalapril to Limit
ccurrences of Thrombosis study (CAMELOT) indicated that the
isk of cardiovascular events in the amlodipine group was 31%
ower than in the placebo group, and that amlodipine inhibited a
rogression of atherosclerosis observed on an intravascular ultra-
ound (IVUS)-guided procedure [30]. Furthermore, amlodipine
igniﬁcantly reduced the incidence of angina requiring hospital-
zation compared to enarapril, although there was no signiﬁcant
ifference in the blood pressure-lowering effect.
The vasoprotective actions of amlodipine may  be associ-
ted with its chemical structure. Mason et al. suggested that
nique features of amlodipine contribute to anti-arteriosclerotic
ffects such as antioxidant [31], anti-inﬂammatory [32], and
ascular endothelium-protecting actions [33]. In addition, other
tudies indicated that amlodipine inhibited the proliferation of
mooth muscle cells [34] and platelet aggregation [35], exhibit-
ng anti-arteriosclerotic effects. In this study, amlodipine may  have
rotected the blood vessels of CAD patients, reducing the risk of
ACE. Furthermore, the beneﬁcial effects of the combination of
mlodipine and a renin-angiotensin-aldosterone system blocker
n endothelial function have been found to be greater than the
ffect of either drug alone, likely due to additive effects on nitric
xide activity [36]. Furthermore, the difference of effect on the
orning surge in blood pressure among CCBs might be considered
or the results of the present study, as the diurnal blood pressure
s supposed to be related with signiﬁcant biomarkers [37]. The
esults of this study suggest that amlodipine complemented the
ess potent inhibitory effects of candesartan on vascular smooth
uscle growth. It therefore is not unreasonable to suggest that a
ombination of amlodipine and candesartan that speciﬁcally tar-
et hypertension and CAD will potentially produce a more than
dditive beneﬁt in terms of improvement of clinical outcomes and
eduction in vascular risk. Due to a lack of direct comparison among
HP-CCBs in clinical studies [38–40], it is difﬁcult to account for the
esults of the present study. The present intriguing possibility can
e answered only by further study.
tudy strength and limitations
Previous randomized, controlled trials have applied strict crite-
ia to avoid heterogeneities of treatment effects [41]. Recently, it is
ncreasingly common for clinical trials to have several hundred sites
n operation in order to enroll the required number of participants
42]. As a result, baseline characteristics, protocol completion, and
utcomes differed signiﬁcantly among higher vs lower enrolling
ites in a recent clinical trial [42]. In the HIJ-CREATE study, a total of
049 patients were randomized in only 14 clinical centers in which
utual exchange of medical doctors are conducted annually. Con-
equently, above-mentioned inter-institutional differences must
e negligible.
The main limitation of this study was the fact that it wasetrospective and based on subgroup analysis of the prospective
tudy and we did not provide a post hoc power calculation. The
esults must therefore be interpreted with caution. A second lim-
tation was that the number of study subjects was small. Becauseiology 62 (2013) 217–223
the combination of amlodipine and candesartan may  be expected
to demonstrate a 20–30% reduction in the rate of cardiovascular
events from previous studies [13,28], we  estimated a cardiovas-
cular event rate of 20% for the combination of amlodipine and
candesartan, and 30% for the combination of non-amlodipine-DHP-
CCBs and candesartan. Sample calculations were based on 80%
power with a 2-sided signiﬁcance level of 0.05 to detect cardio-
vascular events using a log-rank test. It was  estimated that 296
patients were required in each group. Thus, the relatively small
number of patients in this sub-analysis was a limitation since it
reduced the statistical power of the analysis. Although the results
of the present sub-analysis demonstrated the beneﬁcial effects of
amlodipine + candesartan on reducing the incidence of MACE, these
results should be conﬁrmed in a larger and adequately powered
sample size trial. Because this study was  not predeﬁned, a bias in
the selection of patients cannot be excluded. Also, there might be a
bias in the selection of CCBs in each medical center. In addition, the
details on the non-amlodipine CCBs, the dose of prescribed CCBs,
and their compliance were not fully investigated. As the effective
doses of amlodipine and candesartan for their combination could
not be clariﬁed, further studies are necessary to clarify this point.
Conclusions
These data suggest that combination therapy with candesar-
tan and amlodipine is useful for reducing the risk of MACE
in CAD patients with hypertension. This therapeutic regimen is
more useful than that with candesartan and non-amlodipine-CCBs,
conﬁrming amlodipine-speciﬁc vasoprotective actions. Because
our sample size was  small, further investigation in larger-scale
prospective randomized studies is required to reach any conclu-
sion as to the superiority of combination therapy with candesartan
and amlodipine.
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